Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

8

US Approved OTC

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Sodium channel protein type I alpha subunit

5

Sodium channel protein type II alpha subunit

5

Sodium channel protein type III alpha subunit

5

Sodium channel protein type VIII alpha subunit

5

Dopamine D1 receptor

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

10

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1938

5

1954

3

2000

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Seizures

5

Status epilepticus

5

Acute intermittent porphyria

3

Manic-depressive disease

3

Nausea and vomiting

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

8

Palliative

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

8

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Parke Davis

5

Rhône-Poulenc

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

10

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

EVMPD

10

FDA UNII

10

PUBCHEM

10

SMS_ID

10

CAS

9

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIEPILEPTICS

2

PSYCHOLEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIEPILEPTICS

2

ANTIPSYCHOTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Hydantoin derivatives

2

Phenothiazines with aliphatic side-chain

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

7

Principal Form

3

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 10 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CHLORPROMAZINE

U42B7VYA4P

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1954

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 2a (5-HT2a) receptor

Dopamine D1 receptor

Histamine H1 receptor

Dopamine D2 receptor

Conditions:

Acute intermittent porphyria

Nausea and vomiting

Manic-depressive disease

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on...

multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

PHENYTOIN

6158TKW0C5

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

Epinephrine,(±)-

GR0L9S3J0F

Export Data
Search for Structure

Status:

US Approved OTC

First approved in 2000

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Adrenergic receptor

Conditions:

Racepinephrine or racemic epinephrine is a mixture of levo and dextro isomers of epinephrine act as a nonselective agonist at adrenergic receptors. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including ...

wheezing, shortness of breath. Inhaled racepinephrine became available in September 2012 as a nonprescription treatment for bronchospasm based on a 1986 US Food and Drug Administration rule. Besides, racemic epinephrine relieves respiratory distress in hospitalized infants with bronchiolitis and is safe but does not abbreviate hospital stay. Morbidity associated with bronchiolitis as identified by parents persists for at least one week after hospital discharge in most infants.

CHLORPROMAZINE HIBENZATE

657G38Q829

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1954

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 2a (5-HT2a) receptor

Dopamine D1 receptor

Histamine H1 receptor

Dopamine D2 receptor

Conditions:

Acute intermittent porphyria

Nausea and vomiting

Manic-depressive disease

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on...

multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

CHLORPROMAZINE HYDROCHLORIDE

9WP59609J6

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1954

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 2a (5-HT2a) receptor

Dopamine D1 receptor

Histamine H1 receptor

Dopamine D2 receptor

Conditions:

Acute intermittent porphyria

Nausea and vomiting

Manic-depressive disease

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on...

multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

FOSPHENYTOIN

B4SF212641

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

FOSPHENYTOIN SODIUM HEPTAHYDRATE

9X1NTA9SRP

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

PHENYTOIN SODIUM

4182431BJH

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

FOSPHENYTOIN SODIUM

7VLR55452Z

Export Data
Search for Structure

Status:

US Approved Rx (1996)

First approved in 1938

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Sodium channel protein type III alpha subunit

Sodium channel protein type I alpha subunit

Sodium channel protein type VIII alpha subunit

Sodium channel protein type II alpha subunit

Conditions:

Status epilepticus

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX®...

(fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na channels in the plasma membrane of neurons undergoing seizure activity.

RACEPINEPHRINE HYDROCHLORIDE

336096P2WE

Export Data
Search for Structure

Status:

US Approved OTC

First approved in 2000

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Adrenergic receptor

Conditions:

Racepinephrine or racemic epinephrine is a mixture of levo and dextro isomers of epinephrine act as a nonselective agonist at adrenergic receptors. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including ...

wheezing, shortness of breath. Inhaled racepinephrine became available in September 2012 as a nonprescription treatment for bronchospasm based on a 1986 US Food and Drug Administration rule. Besides, racemic epinephrine relieves respiratory distress in hospitalized infants with bronchiolitis and is safe but does not abbreviate hospital stay. Morbidity associated with bronchiolitis as identified by parents persists for at least one week after hospital discharge in most infants.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1